Skip to main content

Table 1 Demographic and clinical characteristics of fatigued vs.nonfatigued subjects

From: Clinical characteristics of fatigued Parkinson’s patients and the response to dopaminergic treatment

Characteristic Nonfatigued Fatigued P -value
Male (n= 222) 54 (60.00 %) 64(48.48 %) 0.101
Age, y 61.63 ± 9.49 62.50 ± 10.21 0.524
Onset age, y (n= 222) 57.88 ± 9.77 57.89 ± 10.51 0.992
Duration of disease, y (n= 222) 3.75 ± 3.26 4.61 ± 2.99 0.046*
Education, y (n= 222) 10.61 ± 3.12 9.80 ± 3.69 0.09
LEDD (mg/day) (n= 222) 211.19 ± 263.18 280.24 ± 304.04 0.081
H-Y stage (n= 222) 1.73 ± 0.78 2.00 ± 0.76 0.009*
UPDRS total score (n= 222) 39.43 ± 20.26 52.39 ± 20.19 <0.001*
UPDRS part I (n= 222) 2.93 ± 1.93 4.19 ± 2.26 <0.001*
UPDRS part II (n= 222) 9.88 ± 4.80 12.57 ± 5.72 <0.001*
UPDRS part III (n= 222) 25.76 ± 15.37 33.53 ± 14.66 <0.001*
 Postural/gait (sum of UPDRS item 27–30) 3.28 ± 2.80 4.80 ± 3.07 <0.001*
 Bradykinesia (sum of UPDRS item 23–26,31) 12.30 ± 7.98 15.9 ± 7.35 0.001*
 Rigidity (UPDRS item 22) 4.87 ± 4.23 6.45 ± 4.36 0.008*
 Tremor (sum of UPDRS item20 and item21) 3.36 ± 3.26 3.78 ± 3.88 0.391
UPDRS IV (n= 222) 0.86 ± 1.65 1.70 ± 2.57 0.007*
MoCA (n= 222) 22.87 ± 4.59 21.85 ± 4.27 0.066
HAMD (n= 177) 7.26 ± 5.47 9.32 ± 5.17 0.006*
PDSS (n= 177) 119.10 ± 23.65 98.82 ± 25.74 <0.001*
  1. Data are expressed as numbers, with percentages in parentheses, or as mean ± SD. *Significant difference. H-Y stage Hoehn & Yahr staging, LEDD levodopa equivalent daily dosage, UPDRS Unified Parkinson’ Disease Rating Scale, MoCA Montreal Cognitive Assessment, HAMD Hamilton Depression Scale score, PDSS Parkinson’s Disease Sleep Scale